Literature DB >> 2405739

Multicenter study of general anesthesia. II. Results.

J B Forrest1, M K Cahalan, K Rehder, C H Goldsmith, W J Levy, L Strunin, W Bota, C D Boucek, R F Cucchiara, S Dhamee.   

Abstract

A prospective, stratified, randomized clinical trial of the safety and efficacy of four general anesthetic agents (enflurane, fentanyl, halothane, and isoflurane) was conducted in 17,201 patients (study population). Patients were studied before, during, and after anesthesia for up to 7 days. Nineteen patients died (0.11%), and in seven of these (0.04%) the anesthetic may have been a contributing factor. The rates of death, myocardial infarction, and stroke in the study population were so low (less than 0.15%) that no conclusions regarding the relative rates of these outcomes among the four anesthetic agents could be reached. The rates of 16 of 66 types of adverse outcomes in the study population were significantly different among the four study agents. Most of these outcomes were minor. However, severe ventricular arrhythmia (P less than 10(-6)) was more common with halothane, severe hypertension (P less than 10(-6)) and severe bronchospasm (P = 0.028) were more common with fentanyl, and severe tachycardia (P = 0.001) was more common with isoflurane. Recovery from anesthesia during the first 30 min was slowest in those patients who received halothane (P less than or equal to 0.001). In addition, patients who received fentanyl experienced less pain during the first hour in the recovery room (P less than 10(-6)). In conclusion, clinically important differences do exist for some outcomes among the four study agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405739     DOI: 10.1097/00000542-199002000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  18 in total

1.  Specific elements of a new hemodynamics display improves the performance of anesthesiologists.

Authors:  G T Blike; S D Surgenor; K Whalen; J Jensen
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

2.  A graphical object display improves anesthesiologists' performance on a simulated diagnostic task.

Authors:  G T Blike; S D Surgenor; K Whalen
Journal:  J Clin Monit Comput       Date:  1999-01       Impact factor: 2.502

3.  The Canadian four-centre study of anaesthetic outcomes: II. Can outcomes be used to assess the quality of anaesthesia care?

Authors:  M M Cohen; P G Duncan; W D Pope; D Biehl; W A Tweed; L MacWilliam; R N Merchant
Journal:  Can J Anaesth       Date:  1992-05       Impact factor: 5.063

4.  Anaesthesia training and development in Nepal 1985-1990.

Authors:  J R Maltby; R Amatya; N B Rana; B M Shrestha; T M Tuladhar; T J McCaughey
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 5.  Anesthesia.

Authors:  J Appleby; V A Lawrence
Journal:  J Gen Intern Med       Date:  1994-11       Impact factor: 5.128

6.  Choice of anaesthetic regimen influences haemodynamic response to cemented arthroplasty.

Authors:  C B Guest; R J Byrick; C D Mazer; D F Wigglesworth; J B Mullen; J H Tong
Journal:  Can J Anaesth       Date:  1995-10       Impact factor: 5.063

7.  Epidural morphine reduces the risk of postoperative myocardial ischaemia in patients with cardiac risk factors.

Authors:  W S Beattie; D N Buckley; J B Forrest
Journal:  Can J Anaesth       Date:  1993-06       Impact factor: 5.063

Review 8.  [Postoperative nausea and vomiting].

Authors:  C C Apfel; N Roewer
Journal:  Anaesthesist       Date:  2004-04       Impact factor: 1.041

9.  Rate and prognosis of patients under conscious sedation requiring emergent intubation during neuroendovascular procedures.

Authors:  A E Hassan; U Akbar; S A Chaudhry; W G Tekle; R P Tummala; G J Rodriguez; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-31       Impact factor: 3.825

Review 10.  Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.